Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease Eisai Jan 07, 2025 08:14 HKT/SGT Read More
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases Eisai Dec 23, 2024 16:22 HKT/SGT Read More
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico Eisai Dec 05, 2024 10:22 HKT/SGT Read More
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Eisai Nov 28, 2024 15:26 HKT/SGT Read More
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Eisai Nov 26, 2024 14:50 HKT/SGT Read More
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System Olympus Nov 19, 2024 14:30 HKT/SGT Read More
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease Eisai Nov 15, 2024 13:31 HKT/SGT Read More
ニュートン バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第 2 号ファンドより、⽇本初の投資を発表 Newton Biocapital Nov 14, 2024 11:00 JST Read More
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 NEC Corporation Nov 08, 2024 09:31 HKT/SGT Read More
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting NEC Corporation Nov 07, 2024 10:40 HKT/SGT Read More
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" Eisai Nov 05, 2024 10:35 HKT/SGT Read More
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status Eisai Nov 01, 2024 12:56 HKT/SGT Read More
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference Eisai Oct 31, 2024 12:56 HKT/SGT Read More
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) Eisai Oct 31, 2024 10:33 HKT/SGT Read More
Machine learning can predict the mechanical properties of polymers Science and Technology of Advanced Materials Oct 26, 2024 23:08 JST Read More
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study Lexaria Bioscience Oct 22, 2024 21:20 HKT/SGT Read More
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association Eisai Oct 17, 2024 19:01 HKT/SGT Read More
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia Eisai Oct 17, 2024 14:59 HKT/SGT Read More
